Protalix BioTherapeutics has successfully achieved landmark Food and Drug Administration approvals for therapeutic proteins produced through its proprietary plant cell-based expression system. Its commercialized achievements include getting regulatory clearance for Elelyso for the treatment of Gaucher disease and securing subsequent FDA approval for Elfabrio (pegunigalsidase alfa-iwxj) for adult patients with Fabry disease, validated through its ongoing strategic partnerships.